Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.145 +0.105 (+5.15%)
Streaming Delayed Price Updated: 1:18 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $15 Million Public Offering of Common Stock and Warrants
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Proposed Public Offering of Common Stock and Warrants
Via Investor Brand Network
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
Via Chartmill
News headline image
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports First-Quarter Progress Across Phase 3 Alzheimer’s and Parkinson’s Programs
Via Investor Brand Network
News headline image
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO to Present Alzheimer’s Multi-Protein Research at Fierce Biotech Week 2026
Via Investor Brand Network
News headline image
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks are being observed in Monday's session. ↗
Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $10 Million Offering To Fund Phase 3 Milestones Through 2027
Via Investor Brand Network
News headline image
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
From Annovis Bio Inc.
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication
Via Investor Brand Network
News headline image
Annovis Publishes Historical Review of Buntanetap in The Scientist
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Partners With NeuroRPM To Integrate AI Platform In Parkinson Study
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
From NeuroRPM Inc.
Via GlobeNewswire
News headline image
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives Positive DSMB Recommendation to Continue Phase 3 Alzheimer’s Trial
Via Investor Brand Network
News headline image
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Launch Open-Label Extension Study of Buntanetap in Parkinson Disease
Via Investor Brand Network
News headline image
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
From Annovis Bio Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.